Evonik has closed its acquisition of the Lactel absorbable polymers product line from Durect. All Durect employees associated with th business in Birmingham, Alabama accepted the offer to join Evonik in similar roles.
“The acquisition of the Lactel business will strengthen both our innovation growth field healthcare solutions and Evonik’s position as a globally leading CDMO for drug delivery solutions”, said Johann-Caspar Gammelin, Head of the Nutrition & Care Division of Evonik.
Poly(lactide-co-glycolide) (PLG or PLGA) polymers are used as a functional excipient to control the release of parenteral drug products. They are also used to control the biodegradation of implantable medical devices across various orthopaedic, cardiovascular, wound healing and other applications.
“The integration of the Lactel business into Evonik’s market-leading portfolio of functional excipients, biomaterials and integrated CDMO services will strengthen our position as a preferred development partner and solutions provider,” said Thomas Riermeier, Head of the Health Care business line. “By welcoming Lactel and members of their team into the Evonik family, we look forward to providing customers with even greater platform versatility as well as other value-adding services."
